首页 > 最新文献

British Journal of Psychiatry最新文献

英文 中文
Association between a selective 5-HT4 receptor agonist and incidence of major depressive disorder: emulated target trial. 选择性 5-HT4 受体激动剂与重度抑郁症发病率之间的关系:模拟目标试验。
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 DOI: 10.1192/bjp.2024.97
Angharad N de Cates, Catherine J Harmer, Paul J Harrison, Philip J Cowen, Anton Emmanuel, Simon Travis, Susannah E Murphy, Maxime Taquet

Background: The serotonin 4 receptor (5-HT4R) is a promising target for the treatment of depression. Highly selective 5-HT4R agonists, such as prucalopride, have antidepressant-like and procognitive effects in preclinical models, but their clinical effects are not yet established.

Aims: To determine whether prucalopride (a 5-HT4R agonist and licensed treatment for constipation) is associated with reduced incidence of depression in individuals with no past history of mental illness, compared with anti-constipation agents with no effect on the central nervous system.

Method: Using anonymised routinely collected data from a large-scale USA electronic health records network, we conducted an emulated target trial comparing depression incidence over 1 year in individuals without prior diagnoses of major mental illness, who initiated treatment with prucalopride versus two alternative anti-constipation agents that act by different mechanisms (linaclotide and lubiprostone). Cohorts were matched for 121 covariates capturing sociodemographic factors, and historical and/or concurrent comorbidities and medications. The primary outcome was a first diagnosis of major depressive disorder (ICD-10 code F32) within 1 year of the index date. Robustness of the results to changes in model and population specification was tested. Secondary outcomes included a first diagnosis of six other neuropsychiatric disorders.

Results: Treatment with prucalopride was associated with significantly lower incidence of depression in the following year compared with linaclotide (hazard ratio 0.87, 95% CI 0.76-0.99; P = 0.038; n = 8572 in each matched cohort) and lubiprostone (hazard ratio 0.79, 95% CI 0.69-0.91; P < 0.001; n = 8281). Significantly lower risks of all mood disorders and psychosis were also observed. Results were similar across robustness analyses.

Conclusions: These findings support preclinical data and suggest a role for 5-HT4R agonists as novel agents in the prevention of major depression. These findings should stimulate randomised controlled trials to confirm if these agents can serve as a novel class of antidepressant within a clinical setting.

背景:血清素4受体(5-HT4R)是治疗抑郁症的一个很有前景的靶点。目的:与对中枢神经系统无影响的抗便秘药物相比,确定普鲁卡必利(一种 5-HT4R 激动剂,获准用于治疗便秘)是否与降低既往无精神病史者的抑郁症发病率有关:利用从美国大型电子健康记录网络中收集的匿名常规数据,我们进行了一项仿真目标试验,比较了普鲁卡必利与两种作用机制不同的抗便秘药物(利纳氯肽和卢比前列酮)在开始治疗的一年中,既往无重大精神疾病诊断史的患者的抑郁症发病率。研究人员根据 121 个协变因素(包括社会人口因素、历史和/或并发症及药物)对各组进行了匹配。主要结果是在指数日期后 1 年内首次诊断出重度抑郁障碍(ICD-10 代码 F32)。测试了结果对模型和人群规格变化的稳健性。次要结果包括首次诊断为其他六种神经精神疾病:与利那洛肽(危险比为 0.87,95% CI 为 0.76-0.99;P = 0.038;每个匹配队列中的人数 = 8572)和卢比前列酮(危险比为 0.79,95% CI 为 0.69-0.91;P < 0.001;人数 = 8281)相比,普鲁卡必利治疗与次年抑郁症发病率显著降低相关。此外,还观察到所有情绪障碍和精神病的风险显著降低。各项稳健性分析的结果相似:这些研究结果支持临床前数据,并表明 5-HT4R 激动剂可作为新型药物预防重度抑郁症。这些研究结果应促进随机对照试验的开展,以确认这些药物是否能作为一种新型抗抑郁药物应用于临床。
{"title":"Association between a selective 5-HT<sub>4</sub> receptor agonist and incidence of major depressive disorder: emulated target trial.","authors":"Angharad N de Cates, Catherine J Harmer, Paul J Harrison, Philip J Cowen, Anton Emmanuel, Simon Travis, Susannah E Murphy, Maxime Taquet","doi":"10.1192/bjp.2024.97","DOIUrl":"10.1192/bjp.2024.97","url":null,"abstract":"<p><strong>Background: </strong>The serotonin 4 receptor (5-HT<sub>4</sub>R) is a promising target for the treatment of depression. Highly selective 5-HT<sub>4</sub>R agonists, such as prucalopride, have antidepressant-like and procognitive effects in preclinical models, but their clinical effects are not yet established.</p><p><strong>Aims: </strong>To determine whether prucalopride (a 5-HT<sub>4</sub>R agonist and licensed treatment for constipation) is associated with reduced incidence of depression in individuals with no past history of mental illness, compared with anti-constipation agents with no effect on the central nervous system.</p><p><strong>Method: </strong>Using anonymised routinely collected data from a large-scale USA electronic health records network, we conducted an emulated target trial comparing depression incidence over 1 year in individuals without prior diagnoses of major mental illness, who initiated treatment with prucalopride versus two alternative anti-constipation agents that act by different mechanisms (linaclotide and lubiprostone). Cohorts were matched for 121 covariates capturing sociodemographic factors, and historical and/or concurrent comorbidities and medications. The primary outcome was a first diagnosis of major depressive disorder (ICD-10 code F32) within 1 year of the index date. Robustness of the results to changes in model and population specification was tested. Secondary outcomes included a first diagnosis of six other neuropsychiatric disorders.</p><p><strong>Results: </strong>Treatment with prucalopride was associated with significantly lower incidence of depression in the following year compared with linaclotide (hazard ratio 0.87, 95% CI 0.76-0.99; <i>P</i> = 0.038; <i>n</i> = 8572 in each matched cohort) and lubiprostone (hazard ratio 0.79, 95% CI 0.69-0.91; <i>P</i> < 0.001; <i>n</i> = 8281). Significantly lower risks of all mood disorders and psychosis were also observed. Results were similar across robustness analyses.</p><p><strong>Conclusions: </strong>These findings support preclinical data and suggest a role for 5-HT<sub>4</sub>R agonists as novel agents in the prevention of major depression. These findings should stimulate randomised controlled trials to confirm if these agents can serve as a novel class of antidepressant within a clinical setting.</p>","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":" ","pages":"371-378"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mortality associated with clozapine: what is the evidence? 与氯氮平相关的死亡率:证据是什么?
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 DOI: 10.1192/bjp.2024.88
Emilio Fernandez-Egea, Robert J Flanagan, David Taylor, Fiona Gaughran, Stephen M Lawrie, Christopher Jenkins, Shubulade Smith, Oliver D Howes, James H MacCabe

While clozapine has risks, relative risk of fatality is overestimated. The UK pharmacovigilance programme is efficient, but comparisons with other drugs can mislead because of reporting variations. Clozapine actually lowers mortality, partly by reducing schizophrenia-related suicides, but preventable deaths still occur. Clozapine should be used earlier and more widely, but there should be better monitoring and better management of toxicity.

虽然氯氮平有风险,但死亡的相对风险被高估了。英国的药物警戒计划效率很高,但由于报告的差异,与其他药物的比较可能会产生误导。氯氮平实际上降低了死亡率,部分原因是减少了与精神分裂症有关的自杀,但仍有可预防的死亡发生。氯氮平应该更早、更广泛地使用,但应该更好地监测和管理毒性。
{"title":"Mortality associated with clozapine: what is the evidence?","authors":"Emilio Fernandez-Egea, Robert J Flanagan, David Taylor, Fiona Gaughran, Stephen M Lawrie, Christopher Jenkins, Shubulade Smith, Oliver D Howes, James H MacCabe","doi":"10.1192/bjp.2024.88","DOIUrl":"10.1192/bjp.2024.88","url":null,"abstract":"<p><p>While clozapine has risks, relative risk of fatality is overestimated. The UK pharmacovigilance programme is efficient, but comparisons with other drugs can mislead because of reporting variations. Clozapine actually lowers mortality, partly by reducing schizophrenia-related suicides, but preventable deaths still occur. Clozapine should be used earlier and more widely, but there should be better monitoring and better management of toxicity.</p>","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":" ","pages":"357-359"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The potential unintended consequences of Mental Health Act reforms in England and Wales on people with intellectual disability and/or autism: commentary, author response, Tromans et al. 英格兰和威尔士《精神健康法》改革对智障者和/或自闭症患者的潜在意外后果:评论,作者回应,Tromans 等人。
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 Epub Date: 2024-11-04 DOI: 10.1192/bjp.2024.58
Samuel Tromans, Indermeet Sawhney, Rohit Shankar
{"title":"The potential unintended consequences of Mental Health Act reforms in England and Wales on people with intellectual disability and/or autism: commentary, author response, Tromans et al.","authors":"Samuel Tromans, Indermeet Sawhney, Rohit Shankar","doi":"10.1192/bjp.2024.58","DOIUrl":"https://doi.org/10.1192/bjp.2024.58","url":null,"abstract":"","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":"225 3","pages":"414-415"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of nature on the mental health and well-being of children and adolescents: meta-review. 大自然对儿童和青少年心理健康和幸福的影响:荟萃综述。
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 DOI: 10.1192/bjp.2024.109
Tessa Lomax, Joseph Butler, Andrea Cipriani, Ilina Singh

Background: Urbanisation is taking place worldwide and rates of mental illness are rising. There has been increasing interest in 'nature' and how it may benefit mental health and well-being.

Aims: To understand how the literature defines nature; what the characteristics of the nature intervention are; what mental health and well-being outcomes are being measured; and what the evidence shows, in regard to how nature affects the mental health and well-being of children and adolescents.

Method: A meta-review was conducted, searching three databases for relevant primary and secondary studies, using key search terms including 'nature' and 'mental health' and 'mental well-being'. Inclusion criteria included published English-language studies on the child and adolescent population. Authors identified the highest quality evidence from studies meeting the inclusion criteria. Data were extracted and analysed using descriptive content analysis.

Results: Sixteen systematic reviews, two scoping reviews and five good quality cohort studies were included. 'Nature' was conceptualised along a continuum (the 'nature research framework') into three categories: a human-designed environment with natural elements; a human-designed natural environment; and a natural environment. The nature 'intervention' falls into three areas (the 'nature intervention framework'): access, exposure and engagement with nature, with quantity and quality of nature relevant to all areas. Mental health and well-being outcomes fit along a continuum, with 'disorder' at one end and 'well-being' at the other. Nature appears to have a beneficial effect, but we cannot be certain of this.

Conclusions: Nature appears to have a beneficial effect on mental health and well-being of children and adolescents. Evidence is lacking on clinical populations, ethnically diverse populations and populations in low- and middle-income countries. Our results should be interpreted considering the limitations of the included studies and confidence in findings.

背景城市化正在全球范围内进行,精神疾病的发病率也在不断上升。目的:了解文献如何定义 "自然";"自然 "干预的特点是什么;测量的心理健康和幸福结果是什么;以及关于 "自然 "如何影响儿童和青少年的心理健康和幸福的证据是什么:我们使用 "自然"、"心理健康 "和 "心理健康 "等关键搜索词,在三个数据库中搜索了相关的一级和二级研究,并进行了元综述。纳入标准包括已发表的针对儿童和青少年群体的英语研究。作者从符合纳入标准的研究中找出质量最高的证据。采用描述性内容分析法对数据进行提取和分析:结果:共纳入了 16 篇系统综述、2 篇范围界定综述和 5 篇高质量的队列研究。自然 "的概念按照连续统一体("自然研究框架")分为三类:包含自然元素的人类设计环境;人类设计的自然环境;自然环境。自然 "干预 "分为三个方面("自然干预框架"):接触自然、接触自然和参与自然,自然的数量和质量与所有方面相关。心理健康和幸福的结果是一个连续统一体,一端是 "失调",另一端是 "幸福"。自然似乎具有有益的影响,但我们无法确定这一点:结论:大自然似乎对儿童和青少年的心理健康和幸福感有好处。临床人群、不同种族人群以及中低收入国家的人群缺乏这方面的证据。在解释我们的研究结果时,应考虑到所纳入研究的局限性以及对研究结果的信心。
{"title":"Effect of nature on the mental health and well-being of children and adolescents: meta-review.","authors":"Tessa Lomax, Joseph Butler, Andrea Cipriani, Ilina Singh","doi":"10.1192/bjp.2024.109","DOIUrl":"10.1192/bjp.2024.109","url":null,"abstract":"<p><strong>Background: </strong>Urbanisation is taking place worldwide and rates of mental illness are rising. There has been increasing interest in 'nature' and how it may benefit mental health and well-being.</p><p><strong>Aims: </strong>To understand how the literature defines nature; what the characteristics of the nature intervention are; what mental health and well-being outcomes are being measured; and what the evidence shows, in regard to how nature affects the mental health and well-being of children and adolescents.</p><p><strong>Method: </strong>A meta-review was conducted, searching three databases for relevant primary and secondary studies, using key search terms including 'nature' and 'mental health' and 'mental well-being'. Inclusion criteria included published English-language studies on the child and adolescent population. Authors identified the highest quality evidence from studies meeting the inclusion criteria. Data were extracted and analysed using descriptive content analysis.</p><p><strong>Results: </strong>Sixteen systematic reviews, two scoping reviews and five good quality cohort studies were included. 'Nature' was conceptualised along a continuum (the 'nature research framework') into three categories: a human-designed environment with natural elements; a human-designed natural environment; and a natural environment. The nature 'intervention' falls into three areas (the 'nature intervention framework'): access, exposure and engagement with nature, with quantity and quality of nature relevant to all areas. Mental health and well-being outcomes fit along a continuum, with 'disorder' at one end and 'well-being' at the other. Nature appears to have a beneficial effect, but we cannot be certain of this.</p><p><strong>Conclusions: </strong>Nature appears to have a beneficial effect on mental health and well-being of children and adolescents. Evidence is lacking on clinical populations, ethnically diverse populations and populations in low- and middle-income countries. Our results should be interpreted considering the limitations of the included studies and confidence in findings.</p>","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":" ","pages":"401-409"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
British contributions to the therapeutic use of John Cade's lithium. 英国人对约翰-凯德锂疗法的贡献。
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 DOI: 10.1192/bjp.2024.155
Gin S Malhi, Erica Bell

Coinciding with the 75th anniversary of John Cade's seminal publication that first reported lithium's antimanic efficacy, we briefly recount the salient findings of the historic paper and draw attention to the important psychiatric research in Britain that reinforced its findings and the critical British opinions that likely impeded its clinical use.

在约翰-凯德首次报道锂的抗躁狂症疗效的开创性出版物发表 75 周年之际,我们简要回顾了这篇历史性论文的主要发现,并提请注意英国重要的精神病学研究,这些研究强化了论文的发现,而英国的批评意见很可能阻碍了论文的临床应用。
{"title":"British contributions to the therapeutic use of John Cade's lithium.","authors":"Gin S Malhi, Erica Bell","doi":"10.1192/bjp.2024.155","DOIUrl":"10.1192/bjp.2024.155","url":null,"abstract":"<p><p>Coinciding with the 75th anniversary of John Cade's seminal publication that first reported lithium's antimanic efficacy, we briefly recount the salient findings of the historic paper and draw attention to the important psychiatric research in Britain that reinforced its findings and the critical British opinions that likely impeded its clinical use.</p>","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":" ","pages":"353-356"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Equanimity in psychiatric medicine: the mind in the middle - Psychiatry in history. 精神病学中的平和心态:中庸之道 - 历史上的精神病学。
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 Epub Date: 2024-11-04 DOI: 10.1192/bjp.2024.63
Michael Uebel
{"title":"Equanimity in psychiatric medicine: the mind in the middle - Psychiatry in history.","authors":"Michael Uebel","doi":"10.1192/bjp.2024.63","DOIUrl":"https://doi.org/10.1192/bjp.2024.63","url":null,"abstract":"","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":"225 3","pages":"413"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study: commentary, Fazel. 渗透释放口服系统哌醋甲酯对患有注意缺陷多动障碍的年轻男性囚犯的症状和行为结果的短期影响的随机对照试验:CIAO-II研究:评论,法泽尔。
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 Epub Date: 2024-11-04 DOI: 10.1192/bjp.2024.59
Seena Fazel
{"title":"Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study: commentary, Fazel.","authors":"Seena Fazel","doi":"10.1192/bjp.2024.59","DOIUrl":"https://doi.org/10.1192/bjp.2024.59","url":null,"abstract":"","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":"225 3","pages":"411"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensitivity to light in bipolar disorder: implications for research and clinical practice: commentary, Terao. 双相情感障碍对光的敏感性:对研究和临床实践的影响:评论,Terao.
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 Epub Date: 2024-11-04 DOI: 10.1192/bjp.2024.54
Takeshi Terao
{"title":"Sensitivity to light in bipolar disorder: implications for research and clinical practice: commentary, Terao.","authors":"Takeshi Terao","doi":"10.1192/bjp.2024.54","DOIUrl":"https://doi.org/10.1192/bjp.2024.54","url":null,"abstract":"","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":"225 3","pages":"410"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT). 首发精神病患者耐药风险临床预测模型的开发和初步评估:精神分裂症抗药性预测模型(SPIRIT)。
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 DOI: 10.1192/bjp.2024.101
Saeed Farooq, Miriam Hattle, Tom Kingstone, Olesya Ajnakina, Paola Dazzan, Arsime Demjaha, Robin M Murray, Marta Di Forti, Peter B Jones, Gillian A Doody, David Shiers, Gabrielle Andrews, Abbie Milner, Maria Antonietta Nettis, Andrew J Lawrence, Danielle A van der Windt, Richard D Riley

Background: A clinical tool to estimate the risk of treatment-resistant schizophrenia (TRS) in people with first-episode psychosis (FEP) would inform early detection of TRS and overcome the delay of up to 5 years in starting TRS medication.

Aims: To develop and evaluate a model that could predict the risk of TRS in routine clinical practice.

Method: We used data from two UK-based FEP cohorts (GAP and AESOP-10) to develop and internally validate a prognostic model that supports identification of patients at high-risk of TRS soon after FEP diagnosis. Using sociodemographic and clinical predictors, a model for predicting risk of TRS was developed based on penalised logistic regression, with missing data handled using multiple imputation. Internal validation was undertaken via bootstrapping, obtaining optimism-adjusted estimates of the model's performance. Interviews and focus groups with clinicians were conducted to establish clinically relevant risk thresholds and understand the acceptability and perceived utility of the model.

Results: We included seven factors in the prediction model that are predominantly assessed in clinical practice in patients with FEP. The model predicted treatment resistance among the 1081 patients with reasonable accuracy; the model's C-statistic was 0.727 (95% CI 0.723-0.732) prior to shrinkage and 0.687 after adjustment for optimism. Calibration was good (expected/observed ratio: 0.999; calibration-in-the-large: 0.000584) after adjustment for optimism.

Conclusions: We developed and internally validated a prediction model with reasonably good predictive metrics. Clinicians, patients and carers were involved in the development process. External validation of the tool is needed followed by co-design methodology to support implementation in early intervention services.

背景:目的:开发并评估一种可在常规临床实践中预测耐药精神分裂症(TRS)风险的模型:我们利用英国两个 FEP 队列(GAP 和 AESOP-10)的数据,开发并在内部验证了一个预后模型,该模型可在 FEP 诊断后不久识别出 TRS 高危患者。利用社会人口学和临床预测因子,在惩罚性逻辑回归的基础上建立了一个预测 TRS 风险的模型,并使用多重归因法处理缺失数据。通过引导法进行了内部验证,获得了模型性能的乐观调整估计值。对临床医生进行了访谈和焦点小组讨论,以确定与临床相关的风险阈值,并了解模型的可接受性和感知效用:结果:我们在预测模型中加入了七个因素,这些因素在临床实践中主要用于评估 FEP 患者。该模型预测了 1081 名患者的治疗耐药性,准确度较高;模型的 C 统计量在缩小前为 0.727(95% CI 0.723-0.732),在调整乐观程度后为 0.687。在对乐观程度进行调整后,校准结果良好(预期/观测比:0.999;大校准:0.000584):我们开发并在内部验证了一个预测模型,其预测指标相当不错。临床医生、患者和护理人员都参与了开发过程。需要对该工具进行外部验证,然后采用共同设计的方法来支持早期干预服务的实施。
{"title":"Development and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT).","authors":"Saeed Farooq, Miriam Hattle, Tom Kingstone, Olesya Ajnakina, Paola Dazzan, Arsime Demjaha, Robin M Murray, Marta Di Forti, Peter B Jones, Gillian A Doody, David Shiers, Gabrielle Andrews, Abbie Milner, Maria Antonietta Nettis, Andrew J Lawrence, Danielle A van der Windt, Richard D Riley","doi":"10.1192/bjp.2024.101","DOIUrl":"10.1192/bjp.2024.101","url":null,"abstract":"<p><strong>Background: </strong>A clinical tool to estimate the risk of treatment-resistant schizophrenia (TRS) in people with first-episode psychosis (FEP) would inform early detection of TRS and overcome the delay of up to 5 years in starting TRS medication.</p><p><strong>Aims: </strong>To develop and evaluate a model that could predict the risk of TRS in routine clinical practice.</p><p><strong>Method: </strong>We used data from two UK-based FEP cohorts (GAP and AESOP-10) to develop and internally validate a prognostic model that supports identification of patients at high-risk of TRS soon after FEP diagnosis. Using sociodemographic and clinical predictors, a model for predicting risk of TRS was developed based on penalised logistic regression, with missing data handled using multiple imputation. Internal validation was undertaken via bootstrapping, obtaining optimism-adjusted estimates of the model's performance. Interviews and focus groups with clinicians were conducted to establish clinically relevant risk thresholds and understand the acceptability and perceived utility of the model.</p><p><strong>Results: </strong>We included seven factors in the prediction model that are predominantly assessed in clinical practice in patients with FEP. The model predicted treatment resistance among the 1081 patients with reasonable accuracy; the model's C-statistic was 0.727 (95% CI 0.723-0.732) prior to shrinkage and 0.687 after adjustment for optimism. Calibration was good (expected/observed ratio: 0.999; calibration-in-the-large: 0.000584) after adjustment for optimism.</p><p><strong>Conclusions: </strong>We developed and internally validated a prediction model with reasonably good predictive metrics. Clinicians, patients and carers were involved in the development process. External validation of the tool is needed followed by co-design methodology to support implementation in early intervention services.</p>","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":" ","pages":"379-388"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in incidence of self-harm, neurodevelopmental and mental health conditions among university students compared with the general population: nationwide electronic data linkage study in Wales. 与普通人群相比,大学生自我伤害、神经发育和精神健康状况的发病率趋势:威尔士全国电子数据链接研究。
IF 8.7 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-01 DOI: 10.1192/bjp.2024.90
Ann John, Olivier Y Rouquette, Sze Chim Lee, Jo Smith, Marcos Del Pozo Baños

Background: Concern that self-harm and mental health conditions are increasing in university students may reflect widening access to higher education, existing population trends and/or stressors associated with this setting.

Aims: To compare population-level data on self-harm, neurodevelopmental and mental health conditions between university students and non-students with similar characteristics before and during enrolment.

Method: This cohort study linked electronic records from the Higher Education Statistics Agency for 2012-2018 to primary and secondary healthcare records. Students were undergraduates aged 18 to 24 years at university entry. Non-students were pseudo-randomly selected based on an equivalent age distribution. Logistic regressions were used to calculate odds ratios. Poisson regressions were used to calculate incidence rate ratios (IRR).

Results: The study included 96 760 students and 151 795 non-students. Being male, self-harm and mental health conditions recorded before university entry, and higher deprivation levels, resulted in lower odds of becoming a student and higher odds of drop-out from university. IRRs for self-harm, depression, anxiety, autism spectrum disorder (ASD), drug use and schizophrenia were lower for students. IRRs for self-harm, depression, attention-deficit hyperactivity disorder, ASD, alcohol use and schizophrenia increased more in students than in non-students over time. Older students experienced greater risk of self-harm and mental health conditions, whereas younger students were more at risk of alcohol use than non-student counterparts.

Conclusions: Mental health conditions in students are common and diverse. While at university, students require person-centred stepped care, integrated with local third-sector and healthcare services to address specific conditions.

背景:人们对大学生自我伤害和心理健康问题日益增多的关注,可能反映了接受高等教育的机会日益增多,以及现有的人口趋势和/或与高等教育相关的压力:目的:比较具有相似特征的大学生和非大学生在入学前和入学期间的自残、神经发育和精神健康状况的人群数据:这项队列研究将高等教育统计局 2012-2018 年的电子记录与初级和中级医疗保健记录联系起来。学生为大学入学时年龄在18至24岁之间的本科生。非学生是根据同等年龄分布伪随机抽取的。采用逻辑回归计算几率比。泊松回归用于计算发病率比(IRR):研究包括 96 760 名学生和 151 795 名非学生。男性、大学入学前记录的自残和精神健康状况以及较高的贫困水平导致成为学生的几率较低,而从大学辍学的几率较高。学生自残、抑郁、焦虑、自闭症谱系障碍(ASD)、吸毒和精神分裂症的内部比率较低。随着时间的推移,学生自我伤害、抑郁、注意力缺陷多动障碍、自闭症谱系障碍、酗酒和精神分裂症的内部比率比非学生增加得更多。与非学生相比,年龄较大的学生自我伤害和精神健康状况的风险更大,而年龄较小的学生酗酒的风险更高:结论:学生的心理健康问题既常见又多样。在大学期间,学生需要以人为本的阶梯式护理,并与当地第三部门和医疗保健服务相结合,以解决具体问题。
{"title":"Trends in incidence of self-harm, neurodevelopmental and mental health conditions among university students compared with the general population: nationwide electronic data linkage study in Wales.","authors":"Ann John, Olivier Y Rouquette, Sze Chim Lee, Jo Smith, Marcos Del Pozo Baños","doi":"10.1192/bjp.2024.90","DOIUrl":"10.1192/bjp.2024.90","url":null,"abstract":"<p><strong>Background: </strong>Concern that self-harm and mental health conditions are increasing in university students may reflect widening access to higher education, existing population trends and/or stressors associated with this setting.</p><p><strong>Aims: </strong>To compare population-level data on self-harm, neurodevelopmental and mental health conditions between university students and non-students with similar characteristics before and during enrolment.</p><p><strong>Method: </strong>This cohort study linked electronic records from the Higher Education Statistics Agency for 2012-2018 to primary and secondary healthcare records. Students were undergraduates aged 18 to 24 years at university entry. Non-students were pseudo-randomly selected based on an equivalent age distribution. Logistic regressions were used to calculate odds ratios. Poisson regressions were used to calculate incidence rate ratios (IRR).</p><p><strong>Results: </strong>The study included 96 760 students and 151 795 non-students. Being male, self-harm and mental health conditions recorded before university entry, and higher deprivation levels, resulted in lower odds of becoming a student and higher odds of drop-out from university. IRRs for self-harm, depression, anxiety, autism spectrum disorder (ASD), drug use and schizophrenia were lower for students. IRRs for self-harm, depression, attention-deficit hyperactivity disorder, ASD, alcohol use and schizophrenia increased more in students than in non-students over time. Older students experienced greater risk of self-harm and mental health conditions, whereas younger students were more at risk of alcohol use than non-student counterparts.</p><p><strong>Conclusions: </strong>Mental health conditions in students are common and diverse. While at university, students require person-centred stepped care, integrated with local third-sector and healthcare services to address specific conditions.</p>","PeriodicalId":9259,"journal":{"name":"British Journal of Psychiatry","volume":" ","pages":"389-400"},"PeriodicalIF":8.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141900929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
British Journal of Psychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1